New CEO Sets Ambitious Growth Target
Shares in Oxford Nanopore Technologies surged after newly appointed Chief Executive Officer Francis Van Parys outlined an ambitious long-term goal of turning the British DNA-sequencing company into a $1 billion-and-growing annual revenue business.
The announcement came alongside the company’s half-year results, which showed stronger revenue growth and a significantly smaller loss. Investors responded positively to the combination of improving financial performance and a clearer growth strategy, sending the shares more than 7% higher during trading on Wednesday.
The company’s more formal financial target calls for annual revenue of more than $700 million by 2030, while Van Parys has described the longer-term ambition as building a business capable of generating $1 billion or more in annual revenue.
Revenue Growth Accelerates
Oxford Nanopore reported revenue of £116.7 million for the six months through June, representing growth of 12.3% on a constant-currency basis.
The company also made progress on profitability. Its first-half loss narrowed to £48 million, compared with a loss of £71.8 million during the same period a year earlier.
The improvement suggests that Oxford Nanopore’s strategy is beginning to generate greater operating leverage as the company expands its customer base and focuses investment on markets where its sequencing technology has the strongest commercial potential.
The results were particularly important for investors because Oxford Nanopore has spent years balancing rapid technological development with the challenge of becoming financially sustainable.
New Leadership Brings a Different Strategy
Francis Van Parys became Oxford Nanopore’s CEO in March 2026, succeeding co-founder Gordon Sanghera, who led the company for more than two decades.
Van Parys brings extensive experience in life sciences and healthcare businesses, including senior positions at Danaher, Cytiva and GE Healthcare. His appointment was intended to help Oxford Nanopore move into its next stage of commercial development after years of technological and scientific expansion.
The new CEO has emphasized a more focused strategy centered on applications where Oxford Nanopore’s technology can generate the greatest commercial value.
Rather than pursuing every possible sequencing market equally, the company plans to concentrate resources on selected opportunities across BioPharma, Clinical and Research markets.
Clinical and Biopharma Demand Shows Strength
Oxford Nanopore’s latest results showed particularly strong growth in its applied markets.
Clinical revenue increased by 35.4%, while BioPharma revenue rose 25%. Industrial revenue increased 6.2%, and Research revenue grew 5.4%.
The figures demonstrate the company’s effort to diversify beyond traditional academic research customers. Oxford Nanopore sees major opportunities in healthcare, pharmaceutical development and industrial applications where rapid and information-rich sequencing could provide significant advantages.
The company is also expanding partnerships designed to move its technology into practical applications. During the period, it announced a licensing agreement with a global diagnostics company and an agreement with California-based genome analysis company MyOme to incorporate Oxford Nanopore sequencing into a rare-disease platform.
PromethION Becomes a Key Growth Engine
One of the company’s most important growth drivers is its PromethION family of sequencing systems.
Revenue from PromethION benchtop DNA and RNA sequencing devices increased 15.7% year over year. These systems are designed for applications ranging from microbial sequencing to large-scale population genomics and complex cancer research.
The growing use of PromethION is important because Oxford Nanopore’s long-term growth depends not only on selling sequencing equipment but also on increasing the frequency with which customers use its technology.
A larger installed base combined with higher utilization can create recurring demand for sequencing consumables and services, strengthening the company’s revenue model over time.
Nanopore Technology Offers a Different Approach
Oxford Nanopore competes in the global DNA-sequencing market with technology based on nanopore sensing.
Its platform allows researchers to analyze DNA and RNA molecules electronically and can provide long-read sequencing capabilities. The technology is being used across research, clinical, pharmaceutical and industrial applications.
The company believes its ability to deliver rapid and information-rich analysis can open applications beyond conventional sequencing markets.
Oxford Nanopore’s scientific footprint has also continued expanding. The company reported more than 4,000 peer-reviewed papers published using its technology during 2025, bringing the total to roughly 20,000.
That scientific adoption provides an important foundation for broader commercial expansion.
Path to Profitability Remains Critical
Despite the improving results, Oxford Nanopore is still not profitable.
The company reported a full-year loss of £145.2 million in 2025, although its adjusted EBITDA loss improved substantially compared with the previous year. Management previously said it expects to reach adjusted EBITDA breakeven in 2027 and become cash-flow positive in 2028.
That timeline makes the company’s revenue growth particularly important.
Investors are likely to judge Van Parys not only on whether Oxford Nanopore can expand sales but also on whether the company can convert that growth into improving margins and eventually sustainable cash generation.
The latest results provide some encouragement because revenue is rising while losses are narrowing.
A Large Market Opportunity
Oxford Nanopore believes its potential markets extend well beyond traditional DNA research.
The company has identified opportunities across clinical diagnostics, pharmaceutical development, industrial biotechnology and research. These markets could expand as sequencing becomes more widely used in areas such as infectious disease testing, cancer research, rare-disease analysis and drug development.
The company’s partnership with Cepheid, a Danaher subsidiary, is one example of its effort to develop automated sequencing solutions for infectious diseases.
If these applications gain wider commercial adoption, Oxford Nanopore could gradually move from being primarily a research technology provider toward becoming a broader life-sciences platform.
Investors Respond to Growth Potential
The strong share-price reaction shows that investors were encouraged by both the financial results and Van Parys’s long-term vision.
Oxford Nanopore shares had faced pressure earlier in the year after the company issued a relatively cautious 2026 growth outlook and announced its new CEO. The stock fell sharply following those announcements as investors questioned whether the company’s growth trajectory could meet expectations.
The latest update has changed the tone.
A combination of stronger first-half performance, improving losses and a clearly articulated long-term ambition has given investors a new reason to reassess the company’s prospects.
However, reaching $1 billion in annual revenue will require substantial growth from current levels and successful expansion into higher-value commercial markets.
Looking Ahead
Oxford Nanopore’s latest results mark an important moment for the company as it begins a new phase under Francis Van Parys.
The immediate financial performance is encouraging, with first-half revenue reaching £116.7 million, strong growth in clinical and biopharma markets, and a narrower loss.
The larger challenge is turning that momentum into sustained profitability and eventually achieving the company’s ambition of becoming a $1 billion-plus annual revenue business.
The formal target of more than $700 million in annual revenue by 2030 provides a nearer-term milestone, while the $1 billion ambition establishes a much larger long-term objective.
If Oxford Nanopore can accelerate adoption of its sequencing technology across healthcare, pharmaceuticals and research while controlling costs, the company could emerge as a significantly larger player in the global genomics industry.
For now, investors appear willing to bet on that possibility. The sharp rise in the stock suggests the market is increasingly focused not on Oxford Nanopore’s past losses, but on whether its technology and new leadership can deliver the scale required for the next stage of growth.
